⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ALXO News
ALX Oncology Holdings Inc. Common Stock
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting
globenewswire.com
ALXO
ALX Oncology to Present at Upcoming Investor Conferences
globenewswire.com
ALXO
ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update
globenewswire.com
ALXO
ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting
globenewswire.com
ALXO
ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference
globenewswire.com
ALXO
ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
globenewswire.com
ALXO